Ascelia Pharma AB Stock price

Equities

ACE

SE0010573113

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm 07:59:56 2024-03-28 am EDT 5-day change 1st Jan Change
9.21 SEK -2.44% Intraday chart for Ascelia Pharma AB -6.50% +173.29%
Sales 2023 - Sales 2024 * - Capitalization 319M 29.83M
Net income 2023 * - Net income 2024 * -37 -3.46 EV / Sales 2023 -
Net cash position 2023 21.86M 2.05M Net cash position 2024 * 18.5M 1.73M EV / Sales 2024 * -
P/E ratio 2023 *
-
P/E ratio 2024 *
-7.35 x
Employees 24
Yield 2023 *
-
Yield 2024 *
-
Free-Float 67.59%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.22%
1 week-6.29%
Current month+14.66%
1 month+19.87%
3 months+176.76%
6 months+140.05%
Current year+173.89%
More quotes
1 week
9.05
Extreme 9.05
11.16
1 month
6.91
Extreme 6.91
11.16
Current year
3.37
Extreme 3.365
11.16
1 year
2.62
Extreme 2.62
17.50
3 years
2.62
Extreme 2.62
44.55
5 years
2.62
Extreme 2.62
66.70
10 years
2.62
Extreme 2.62
66.70
More quotes
Managers TitleAgeSince
Chief Executive Officer 49 13-12-31
Chief Tech/Sci/R&D Officer - 22-10-04
Chief Tech/Sci/R&D Officer - 22-10-04
Members of the board TitleAgeSince
Chairman 69 17-05-31
Director/Board Member 76 99-12-31
Director/Board Member 59 16-12-31
More insiders
Date Price Change Volume
24-03-28 9.21 -2.44% 63 614
24-03-27 9.44 -3.08% 57,242
24-03-26 9.74 -3.75% 190,134
24-03-25 10.12 -5.42% 279,830
24-03-22 10.7 +8.63% 256,062

Delayed Quote Nasdaq Stockholm, March 28, 2024 at 07:45 am EDT

More quotes
Ascelia Pharma AB is a Sweden-based pharmaceutical company focused on the development of novel oncology therapies. The Company identifies, acquires and develops differentiated, underappreciated and derisked investigational medicinal drug candidates to make them available to cancer patients. The Company's pipeline includes Mangoral and Oncoral. Mangoral is a medical imaging drug candidate for use in liver Magnetic Resonance Imaging (MRI) for detection and localization of liver metastases in patients with impaired kidneys, which has completed phase II of clinical studies. Oncoral is a tablet formulation of chemotherapeutic agent irinotecan under clinical development for the treatment of gastric cancer. It has completed phase I of clinical studies.
Calendar
More about the company
  1. Stock
  2. Equities
  3. Stock Ascelia Pharma AB - Nasdaq Stockholm